ArticleApplied biochemistry and biotechnology2026
Interplay of Molecular Subtypes Associated with Butyrate Metabolism Elucidates Clinical Characteristics and Tumor Microenvironment in Prostate Cancer.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emerging evidence underscores the pivotal yet context-dependent role of butyrate metabolism in oncogenic progression; however, the mechanistic landscape of its associated genetic determinants in prostate carcinogenesis remains poorly characterized. This gap presents a critical opportunity to delineate novel metabolic checkpoints that may offer therapeutic vulnerabilities for advanced prostate malignancies. Analyzing prostate cancer (PC) patients from TCGA and GEO databases, we identified 320 BMGs and stratified tumors into two butyrate metabolism-associated clusters. Machine learning and single-cell transcriptome analysis are used for further study. Luciferase reporter assay, qRT-PCR, FISH, and functional assays are applied to investigate the role of FOS. BMC1 correlated with aggressive phenotypes and stromal-rich tumor microenvironments, while BMC2 was linked to cell cycle regulation and DNA repair. A machine learning-derived RSF + GBM prognostic model demonstrated robust predictive accuracy for biochemical recurrence (training C-index: 0.85). BM scores are further associated with tumor mutation burden and differential drug sensitivities. FOS is overexpressed in PC, promotes proliferation and migration via transcriptional suppression of tumor-suppressive miR-27b. Clinical cohorts confirmed FOS's correlation with advanced T stages and recurrence risk. These findings establish BM-based stratification as a prognostic tool and implicate the FOS-miR-27b axis as a therapeutic target, bridging metabolic heterogeneity with molecular mechanisms in PC progression. Our research offers a critical opportunity to delineate novel metabolic checkpoints that may offer therapeutic vulnerabilities for advanced prostate malignancies.
Indexed as
Identifiers
41205043What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.